Molecular Docking study of Catechins compounds from Camellia sinensis against UPPS in Staphylococcus aureus

Anitha Parimelzanghan, Lavanya P, Anand Anbarasu, Sudha Ramaiah

Abstract


Antibiotics resistant Staphylococcus aureus (S. aureus) is an emerging concern in the medical field. Due to their increasing resistance to numerous antibiotics, there is indeed essential to explore both potential targets and effective antibiotics. Therefore, we considered undecaprenyl diphosphate synthase (UPPS) as a potential target as it is an essential enzyme in cell wall biosynthesis of S. aureus. Earlier reports on these four major compounds from Camellia sinensis plant extract such as catechins (C), epicatechin (EC), epicatechin gallate (ECg) and epigallocatechin gallate (EGCg) suggested that it could be an effective antibacterial agent. Thus, we attempt to validate the antibacterial activity of these compounds against UPPS via molecular docking analysis. Interestingly, we found that epicatechin gallate (ECg) has the highest binding energy with UPPS protein by forming nine hydrogen bonds with the amino acid residues at the binding site of the receptor. Hence, our results infer that ECg from Camellia sinensis poses significant anti-bacterial activities. Thus, the aim of this study was to provide an effective antibacterial molecule and potent target which might be helpful in further modification to increase their sensitivity.

Full Text:

PDF

References


Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection, Clin Infect Dis, 2008 Jun; 46 (5): 350-359. Cited in PubMed; PMID: 18462090.

Thati V, Shivannavar CT, Gaddad, SM. Vancomycin resistance among methicillin resistant Staphylococcus aureus isolates from intensive care units of tertiary care hospitals in Hyderabad, Indian J Med Res, 2011 Nov; 134 (5): 704-708. Cited in PubMed; PMID: 22199111.

Llarrull LI, Fisher JF, Mobashery S. Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge, Antimicrob Agents Chemother, 2009 Oct; 53(10): 4051-4063. Cited in PubMed; PMID: 19470504.

Sainsbury S, Bird L, Rao V, Shepherd SM, Stuart DI, Hunter WN, et al. Crystal structures of Penicillin binding protein 3 from Pseudomonas aeruginosa: comparison of native and antibiotic-bound forms. J Mol Biol. 2011 Jan 7; 405 (1):173–184. Cited in PubMed; PMID: 20974151.

Turk S, Verlaine O, Gerards T, Zivec M, Humljan J, Sosic I, et al. New noncovalent Inhibitors of Penicillin-Binding Proteins from Penicillin-Resistant Bacteria. Plos one. 2011 May 9; 6 (5): e19418. Cited in PubMed; PMID: 21573060.

Yoshida H, Kawai F, Obayashi E, Akashi S, Roper DI, Tame JR, et al. Crystal structures of penicillin-binding protein 3 (PBP3) from methicillin-resistant Staphylococcus aureus in the apo and cefotaxime bound forms. J Mol Biol. 2012 Oct 26; 423 (3): 351–364. Cited in PubMed; PMID: 22846910.

Zhu W, Zhan Y, Sinko W, Hensle, ME, Olson J, Molohon KJ, et al. Antibacterial drug leads targeting isoprenoid biosynthesis. Proc Natl Acad Sci U S A. 2013 Jan 2; 110 (1): 123-128. Cited in PubMed; PMID: 23248302.

Heuston S, Begley M, Gahan CG, Hill C. Isoprenoid biosynthesis in bacterial pathogens, Microbiology, 2012 Jun; 158:1389-1401. Cited in PubMed; PMID: 22466083.

Apfel CM, Takács B, Fountoulakis M, Stieger M, Keck W. Use of genomics to identify bacterial undecaprenyl pyrophosphate synthetase: Cloning, expression, and characterization of the essential uppS gene. J Bacteriol. 1999 Jan; 181 (2): 483–492. Cited in PubMed; PMID: 9882662.

Taylor PW, Hamilton-Miller JM, Stapleton PD. Antimicrobial properties of green tea catechins. Food Sci Technol Bull. 2005 Oct; 2: 71-81. Cited in PubMed; PMID: 19844590.

Hirasawa M, Takada K. Multiple effects of green tea catechin on the antifungal activity of antimycotics against Candida albicans. J Antimicrob Chemother. 2004 Feb; 53(2): 225-229. Cited in PubMed; PMID: 14688042.

Shimamura T, Zhao WH, Hu ZQ. Mechanism of Action and Potential for Use of Tea Catechin as an Antiinfective Agent, Anti-Infective Agents in Medicinal Chemistry, 2007 Jan; 6 (1): 57-62.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000 Jan; 28 (1): 235-242. Cited in PubMed; PMID: 10592235.

Li Q, Cheng T, Wang Y, Bryant S H. PubChem as a public resource for drug discovery. Drug Discov Today. 2010 Dec; 15 (23-24): 1052–1057. Cited in PubMed; PMID: 20970519.

SYBYL-X 2.0, Tripos International, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA.

Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol. 1995 Jan; 245 (1): 43-53. Cited in PubMed; PMID: 7823319.

Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des. 1997 Sep; 11 (5): 425-445. Cited in PubMed; PMID: 9385547.

Jarrahpour A, Fathi J, Mimouni M, hadda TB, Sheikh J, Chohan ZH, et al. Petra, Osiris and Molinspiration (POM) together as a successful support in drug design: antibacterial activity and biopharmaceutical characterization of some azo Schiff bases. Med Chem Res. 2011 Aug; 21 (8): 1984-1990.

Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, et al. admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model. 2012 Nov; 52 (11): 3099-3105. Cited in PubMed; PMID: 23092397.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001 Mar; 46 (1-3): 3-26. Cited in PubMed; PMID: 11259830.

Cox RJ, Sutherland A, Vederas, JC. Bacterial diaminopimelate metabolism as a target for antibiotic design. Bioorg Med Chem. 2000 May; 8 (5): 843-871. Cited in PubMed; PMID: 10881998.

Tsaioun K, Bottlaender M, Mabondzo A. Alzheimer's Drug Discovery Foundation. ADDME--Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective. BMC Neurol. 2009 Jun; 9 (1): S1. Cited in PubMed; PMID: 19534730.

Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx. 2005 Oct; 2 (4):554-57. Cited in PubMed; PMID: 16489365.

Thomas VH, Bhattachar S, Hitchingham L, Zocharski P, Naath M, Surendran N, et al. The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol. 2006 Aug; 2 (4): 591-608. Cited in PubMed; PMID: 16859407.

Hurst S, Loi CM, Brodfuehrer J, El-Kattan A. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin Drug Metab Toxicol. 2007 Aug; 3(4): 469-489.Cited in PubMed; PMID: 17696800.